Pemetrexed/ Cisplatin

DRUG2 trials

Sponsors

AstraZeneca, Shandong Cancer Hospital and Institute

Conditions

Non-Small Cell Lung CancerUnresectable Stage III NSCLC

Phase 2

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Shandong Cancer Hospital and InstituteUnresectable Stage III NSCLC

Start: 2021-01-21End: 2023-03-01Target: 35Updated: 2021-08-06

Phase 3

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

CompletedNCT03519971

AstraZenecaNon-Small Cell Lung Cancer

Start: 2018-03-29End: 2026-03-09Updated: 2026-07-14

Related Papers

LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2

ESMO Open2024-03-0161 citations

Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study.

Journal of Clinical Oncology2023-06-013 citations

Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

Frontiers in Oncology2023-02-0219 citations

A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)

Therapeutic Advances in Medical Oncology2021-01-012 citations

PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC.

Journal of Clinical Oncology2019-05-2061 citations